Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 62 Next >>

Filter Applied: dyskinesia (Click to remove)

Isolated Lingual Dyskinesia in Multiple Sclerosis
JAMA Neurol 72:1196-1197, Park, J.E.,et al, 2015

Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014

Anti-NMDA-Receptor Encephalitis: Case Series and Analysis of the Effects of Antibodies
Lancet Neurol 7:1091-1098, Dalmau,J.,et al, 2008

Anti-NMDA-Receptor Encephalitis: Case Series and Analysis of the Effects of Antibodies
Lancet Neurol 7:1091-1098, Dalmau,J.,et al, 2008

Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999

Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023

Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease
Neurol 97:e1367-e1381, Gaig, C.,et al, 2021

Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018

Clnicopathologic Conference Anti-N-Methyl-D-Aspartate (NMDA) Receptor Encephalitis
NEJM 379:870-878, CASE 27-2018, 2018

Paraneoplastic and Autoimmune Encephalitis
UptoDate July, Dalmau, J.,et al, 2017

Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014

Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014

Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014

Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012

Late onset autism and anti-NMDA-receptor encephalitis
Lancet 378:98;378, Creten, C.,et al, 2011

Response to Immunotherapy in a 20-Month-Old Boy With Anti-NMDA Receptor Encephalitis
Neurol 74:1550-1551, Wong-Kisiel,L.C., et al, 2010

Retrospective Analysis of NMDA Receptor Antibodies in Encephalitis of Unknown Origin
Neurol 75:1735-1739, Pr�ss,H.,et al, 2010

Anti-N-Methyl-D-Aspartate Receptor (NHMDAR) Encephalitis in Children and Adolescents
Ann Neurol 66:11-18,1, Florance,N.R.,et al, 2009

N-Methyl-D-Aspartate Receptor Antibodies in Pediatric Dyskinetic Encephalitis Lethargica
Ann Neurol 66:704-709, Dale,R.,et al, 2009

Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006

Diffusion-Weighted Magnetic Resonance Imaging in the Syndrome of Acute Bilateral Basal Ganglia Lesions in Diabetic Uremia
Mov Disord 21:1267-1270, Kim, T.,et al, 2006

Autoantibodies to Folate Receptors in the Cerebral Folate Deficiency Syndrome
NEJM 352:1985-1991, Ramaekers,V.T.,et al, 2005

Etiological and Therapeutical Observations in a Case of Belly Dancers Dyskinesia
Movement Disorders 20:251-253, Linazasoro,G., et al, 2005

Neurologic Manifestations and Outcome of West Nile Virus Infection
JAMA 290:511-515,524,558, Sejvar,J.J.,et al, 2003

Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003

Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002

A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000

Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000

Unilateral Pallidotomy for Parkinson's Disease:Results after More Than 1 Year
JNNP 67:511-517, Schrag,A.,et al, 1999

Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998

Tardive Dyskinesia:Diagnosis, Pathogenesis, and Management
The Neurologist 4:180-187, Trugman,J.M., 1998

Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998

Bilateral High-Frequency Stimulation of the Internal Globus Pallidus in Advanced Parkinson's Disease
Ann Neurol 44:953-961, Volkmann,J.,et al, 1998

Dystonia and Chorea in Acquired Systemic Disorders
JNNP 65:436-445, Janavs,J.L.&Aminoff,M.J., 1998

Low-Dose Clozapine Improves Dyskinesias in Parkinson's Disease
Neurol 48:658-662, Durif,F.,et al, 1997

Tolcapone Improves Motor Function in Parkinsonian Pts with the"Wearing Off"Phenomenon
Neurol 49:1066-1071, Rajput,A.H.,et al, 1997

Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995

Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994

Young-Onset Parkinson's Disease:A Clinical Review
Neurol 41:168-173, Golbe,L.I., 1991

Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991

Movement Disorders in Alcoholism:A Review
Neurol 40:741-746, Neiman,J.,et al, 1990

Levodopa-Induced Dyskinesia:Review, Observations, and Speculations
Neurol 40:340-345, Nutt,J.G., 1990

Involuntary Movement & Bacterial Meningitis
Editorial, Lancet 1:142-1431987., , 1987

Unusual Neurotoxicity Associated with Amiodarone Therapy
Arch Int Med 147:881-884, Palakurthy,P.R.,et al, 1987

Extrapyramidal Reactions with Metoclopramide
BMJ 291:930-932, Bateman,D.N.,et al, 1985

Metoclopramide & Tardive Dyskinesia in the Elderly
BMJ 289:397-398, Orme,M.L., 1984

Onset & End-of-dose Levodopa-induced Dyskinesias
Arch Neurol 35:261, Lhermitte,F.,et al, 1978

Clinical Diagnosis of the Dyskinesias
Med Clin of North Am 56:1321, Duvoisin,R., 1972

NMDA Receptor Encephalitis Mimicking Seronegative Neuromyelitis Optica
Neurol 74:1473-1475, Kruer,M.C., et al, 2010



Showing articles 0 to 50 of 62 Next >>